Edwards Lifesciences Corporation (EW) Q2 2014 Earnings Results

Edwards Lifesciences Beats on EPS, Stock Down 0.54%

Edwards Lifesciences reported better-than-expected earnings per share, which indicates strong operational performance. However, the stock declined slightly by 0.54%, likely due to the lack of revenue details and forward guidance. Investors may be cautious as the company navigates market challenges.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.88	N/A	+14.88%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook on product performance. However, they acknowledged ongoing market pressures.

Management highlighted the strength in their product pipeline.

They expressed confidence in future growth despite current market challenges.

Edwards Lifesciences Beats on EPS, Stock Down 0.54%

Key numbers

Management commentary

Edwards Lifesciences Corporation

More earnings this week

Edwards Lifesciences Beats on EPS, Stock Down 0.54%

Key numbers

Management commentary